BLAINTRAMUSCULARINJECTION, SUSPENSION1 Generic Approved
Approved
Aug 2025
Lifecycle
Launch
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 22h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
mNEXSPIKE is a next-generation mRNA-based COVID-19 vaccine developed by Moderna, approved in August 2025. It utilizes mRNA technology to stimulate immune response against SARS-CoV-2, delivered via intramuscular injection. The vaccine is designed to provide enhanced or sustained protection against COVID-19 variants.
Launch
Early-stage launch presents significant growth opportunity with 185 linked roles; manufacturing and engineering teams are actively scaling production capacity.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
mNEXSPIKE's launch phase creates robust career opportunities across 185 linked roles, with strong demand in manufacturing and engineering. The product's scale-up trajectory offers visibility, cross-functional collaboration, and exposure to mRNA platform innovation within Moderna's expanding vaccine portfolio.
DirectorEngineer II
Worked on mNEXSPIKE at Moderna? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.